August 29, 2019 / 6:33 AM / 2 months ago

AstraZeneca lupus drug meets main goal in study

Aug 29 (Reuters) - AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus, anifrolumab, met its main goal in a late-stage study.

The drug showed a “statistically-significant” and “clinically-meaningful” reduction in the disease in patients with systemic lupus erythematosus, commonly known as SLE, the company said. (Reporting by Noor Zainab Hussain in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below